Alexion to continue APEX-AMI trial for myocardial infarction

By Lisa Kerner

Erie, Pa., Feb. 3 - Alexion Pharmaceuticals, Inc. said it will finalize the ongoing APEX-AMI pexelizumab trial with its partner Procter & Gamble Pharmaceuticals.

With 5,000 patients expected to have enrolled in the study by March, the APEX-AMI pexelizumab trial will be one of the largest acute myocardial infarction trials performed to date, according to a company news release.

"We are very grateful to the hundreds of clinical investigators and thousands of patients around the world who have participated in the APEX-AMI trial and we look forward to reviewing the final data from the trial in the second half of this year," Alexion chief executive officer Leonard Bell said in the release.

Alexion previously reported that a phase 3 trial of pexelizumab in coronary artery bypass graft surgery patients undergoing cardiopulmonary bypass failed to achieve its primary endpoint.

The company said it will continue to focus on regulatory and pre-launch activities of its lead product, Solaris, for the treatment of paroxysmal nocturnal hemoglobinuria. Solaris is currently undergoing two phase 3 trials.

Alexion discovers and develops therapeutic products for the treatment of hematologic and cardiovascular disorders, autoimmune diseases and cancer. The company is based in Cheshire, Conn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.